TARO Chairman Switches Seats

Israeli drugmaker Taro Pharmaceutical Industries (NYSE: TARO  ) has a new CEO -- and a new Chairman of the Board, as well.

On Thursday, Taro announced the imminent retirement of Interim Chief Executive Officer Mr. James Kedrowsk, who will be replaced August 1 by new permanent CEO Mr. Kalyanasundaram Subramanian ("Kal Sundaram"). Additionally, the company said that Dilip Shanghvi has been appointed Chairman of its Board of Directors.

Taro noted that, in taking the CEO's job, "Sundaram" -- formerly the company's Chairman -- is giving up his Chairman's title because Israeli law does not permit one person to be both "Chairman & CEO" of a publicly traded Israeli company. Shanghvi, who had served as Chairman once already, will be taking up that title once again now that Sundaram cannot serve.

As for exiting-CEO Kedrowski, he says he's leaving the firm's employ (but remaining on the Board) "to spend more time with my family." Kedrowski expressed confidence "that Taro is well positioned for the future," without him.

Taro shares shrugged off the news, sitting mostly flat in Thursday trading, and closing at $59.67.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2545360, ~/Articles/ArticleHandler.aspx, 8/30/2014 12:24:05 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement